Gall bladder carcinoma seen in Indian popluation most common in women and presents at a very late stage .Survival is in months hence palliative treatment is being preferred .
3. Gall Bladder Carcinoma
Introduction
• Aggressive malignant disease.
• Extremely poor prognosis.
• No specific presenting symptoms.
• High proportion of patients - advanced disease.
• Earlier stage disease- a more aggressive surgical approach.
4. Gall Bladder Carcinoma
Epidemiology
Incidence
• 6th and 7th decades of life
• 2-3 F>M
• Ethnicity –highest incidence in India and Pakistan.
• Worldwide, the highest incidence rates (up to 8.0 / 100,000 in men and 22 /
100,000 in women) occur among populations in the Indian subcontinent.
• Among North American populations , Native Americans and immigrants from Latin
America have the highest rates.
5. Gall Bladder Carcinoma
Cause
• Chronic inflammation with subsequent cellular proliferation.
• Risk factor – cholelithiasis (7times,90%)
• 3% of gall stone with cholecystitis
• Relative risk- less –size <2cm,2-3cm
• It is 10 or more with >3cm
• Xanthogranulomatous cholecystitis.
6. Gall Bladder Carcinoma
Cause
• Porcelain gall bladder (25%) and 90% of them are inoperable tumours.
• Gallbladder polyp > 10 mm(1cm), >3in no, adenomatous polyp.
• Other risk factors – choledochal cysts
• Cholesteroses of gallbladder
• Primary Sclerosing Cholangitis .
7. Gall Bladder Carcinoma
Cause
• Anomalous pancreaticobiliary duct junction (APBDJ )(20%)
• Chronic typhoid carriers, Inflammatory bowel disease, Hepatitis B and
Hepatitis C virus infection.
• Nitrosamines
• Carcinogen (radon)
8. Gall Bladder Carcinoma
Types
• Gross Types of Carcinoma Gallbladder
• Polypoid /papillary—better prognosis.
• Scirrhous /nodular.
• Proliferative/infiltrative.
9. Gall Bladder Carcinoma
Pathology and staging
• Microscopy
• Commonly - adenocarcinoma (90%); occasionally squamous cell carcinoma,
small cell carcinoma ,lymphoma , sarcoma , adenosquamous or carcinoid
tumor .
• 25% show only localized disease; 35% have lymph node spread; 40% have
distant spread at the time of first diagnosis.
10. Gall Bladder Carcinoma
Pathology and staging contd..
• Dysplasia to carcinoma in situ to invasive carcinoma.
• Altered genes include p53, k-ras, p16ink4a, and erbb2/her2.
• Papillary subtype-indolent course , limited to gall bladder wall , better
prognosis .
• Most gallbladder carcinomas- systemic disease at the time of presentation,
with 35% nodal disease and 40% distant metastases.
11. Gall Bladder Carcinoma
Pathology and staging contd…
• Adenomas -high prevalence β-catenin mutations.
• Dysplastic lesions and cancers associated with APBD - high prevalence of K-
ras mutations and a low prevalence of β-catenin mutations.
• p53 and P16INK4A mutations are not seen in adenomas or dysplastic lesions,
and thus appear to be later events in gallbladder carcinogenesis
12. Gall Bladder Carcinoma
Pathology and staging contd..
• Draining nodal basin -hepatoduodenal ligament periaortic nodes near
the celiac axis or pancreaticoduodenal nodes around the superior mesenteric
artery.
• Direct spread to liver (segment IV and V), bile duct, duodenum, colon and
kidney.
• Blood spread—to liver, lungs and bones.
• Perineural spread
• Transperitoneal spread.
13. Gall Bladder Carcinoma
Staging
Nevin’s staging:
Stage I – Intramural
Stage II – Spread to muscularis propria
Stage III – Spread to serosa
Stage IV – Spread to cystic lymph node of Lund
Stage V – Direct spread to adjacent
organs/metastases
17. Gall Bladder Carcinoma
Clinical presentation
• Location - Fundus and body of gall bladder
• Acute cholecystitis to chronic cholecystitis features
• Weight loss
• Jaundice
• Abdominal mass
• Chronic epigastric pain
• Early satiety
• Fullness
• Hepatomegaly
• Ascites
18. Gall Bladder Carcinoma
Three clinical presentations –
• 1. Clinically obvious type - pain, obstructive jaundice, mass.
• 2. Early GB cancer mimics GB stone disease.
• 3. Atypical as unusual features
19. Gall Bladder Carcinoma
Investigations
• Ultrasound abdomen.
• CT abdomen to see operability.
• US-guided FNAC.
• Liver function tests.
• MRCP.
• Laparoscopy.
• CA 19-9 is elevated in 80% of cases
20. Gall Bladder Carcinoma
Investigation contd…
• Ultrasound of abdomen-irregularly shaped lesion in the subhepatic space,
heterogeneous mass in the gallbladder lumen, and asymmetrically thickened
gallbladder wall .
• Polyp larger than 10 mm should raise the suspicion of gallbladder cancer.
21. Gall Bladder Carcinoma
Investigation contd..
• CT abdomen- staging and treatment
• Peritoneal metastases,
• Hepatic parenchymal metastases,
• Lymphadenopathy,
• And adjacent vascular involvement .
• Triphasic CT can be used to identify
Hepatic arterial or portal venous involvement.
• Percutaneous tissue diagnosis.
22. Gall Bladder Carcinoma
Treatment
• Resection - remains the only potential for cure.
• Patients with gallbladder cancer can be divided into four
• Specific subgroups of presentation:-
Patients with an incidental polyp on imaging,
Patients with an incidental finding of gallbladder cancer at the time of or
after cholecystectomy,
Patients suspected of having gallbladder cancer preoperatively, and
Patients with advanced disease at presentation.
23. Gall Bladder Carcinoma
Treatment
• Gallbladder polyp- > 10 mm-Open cholecystectomy
laparoscopic - may convert a potentially curable disease into an incurable
one.
• Gallbladder cancer after cholecystectomy-
• Depends on depth of penetration of the gallbladder wall and surgical margins.
• T1a (lamina propria)- cholecystectomy (nodal disease<3%)
• T1b-(muscularis,no CT )- cholecystectomy as long as margins are –ve
• T1b (with perineural ,lymphatic and vascular invasion )-Extended
cholecystectomy (Ro resection )
• Port site recurrence- excision of all port site
25. Gall Bladder Carcinoma
Treatment
• Gallbladder cancer after cholecystectomy-
• T2 lesions-muscularis &<= serosa -radical cholecystectomy.
• Standard cholecystectomy alone is not done - 40% of these patients have
lymph node metastases and up to 25% have positive margins.
• Gallbladder cancer is generally unresponsive to other therapies, the presence
of any residual disease after operative intervention predicts poor outcome.
26. Gall Bladder Carcinoma
Treatment
• Patients suspected of having gallbladder cancer preoperatively.
• Resectable cases without metastasis- open cholecystectomy
• Unresectable - diagnostic laparoscopy -to identify small volume peritoneal or
hepatic metastases that would preclude a resection, thereby avoiding an
unnecessary operation.
27. Gall Bladder Carcinoma
Treatment
• Patients suspected of having gallbladder cancer preoperatively.
• Palliative
• T3and T4- Radical resection -segments IVB and V but more often requires a
central hepatectomy, including all of segments IV, V, and VIII.
• For Ro-Direct extension of tumor into adjacent structures such as the hepatic
flexure is not a contraindication to resection as long as negative margins can
be obtained.
• Debulking without possibility of complete resection has no role in the
management of gallbladder cancer.
30. Gall Bladder Carcinoma
Treatment
• Patients with advanced disease at presentation(unresctable and metastatic)
• Advanced Biliary Cancer (ABC)-02 trial, 2010 - locally advanced or metastatic
biliary tract cancer (of whom ~36% had gallbladder cancer) demonstrated that
the combination of gemcitabine + cisplatin (11.7months) is associated with
improved overall and progression-free survival compared to gemcitabine
alone(8.1months)
• Pembrolizumab is now approved for the treatment of patients with all
metastatic and unresectable solid tumors having defective mismatch repair
who have progressed through prior therapy and for whom there are no
satisfactory treatment alternatives.
31. Gall Bladder Carcinoma
Treatment
• Patients with advanced disease at presentation.
• Goal of therapy - palliation of symptoms.
• Jaundice – Endoscopic biliary stent and self expanding endobiliary metal
stent.
•
32. Gall Bladder Carcinoma
Treatment
• Patients with advanced disease at presentation.
• Pain- oral narcotics ,parenteral opioids and Percutaneous neurolysis of the
celiac ganglion.
• Intestinal obstruction-usually gastric outlet obstruction from local extension
of tumor - an endoscopic duodenal wall stent.
33. Gall Bladder Carcinoma
Adjuvant therapy
• Neither chemotherapy nor radiation therapy - survival benefit.
• External beam or intraoperative radiation therapy alone or in combination with 5-
flourouracil (5-fu) has been associated with diminished rates of local recurrence.
• Recently results, of the phase iii multicenter BILCAP trial from the United Kingdom,
were reported.
• Subgroup analysis from an older phase iii trial adjuvant treatment with fluorouracil
and mitomycin c or observation showed improved survival with adjuvant treatment
for patients with gallbladder cancer but not cholangiocarcinoma.
34. Gall Bladder Carcinoma
Survival
• Dependent on the stage of disease at presentation and whether surgical
resection is performed.
• T1a &T1b- excellent prognosis.
• T2 lesions depends on nodal status, and radical resection improves 5-year
survival from approximately 20% to >60%.
35. Gall Bladder Carcinoma
Survival contd …
• 5-year survival rates for patients with T1N0, T2N0, and T3N0 (or no
depositive) disease are 39%, 15%, and 5%, respectively.
• The 5-year survival of patients with T3 tumors is < 20%, and
T4 lesions –months
• Metastatic disease at presentation - median survival of 13 months.
36. Gall Bladder Carcinoma
References
• Sabiston text book of surgery 20th edition pg no-1512-1514.
• SRB manual of surgery 5th edition pg no 659-660
• Maingot’s abdominal operation 13th edition pg no 2989-3009.
• Bailey & Love’s short practice of surgery ,27th edition ,volume 2, pg
no 1209-1211
• Pandey M, Shukla VK. Lifestyle, parity, menstrual and reproductive
factors and risk of gallbladder cancer. Eur J Cancer Prevent. Aug
2003; 12(4):269-272.
• Elnemr A, Ohta T, Kayahara M, et al. Anomalous pancreaticobiliary
ductal junction without bile duct dilatation in gallbladder cancer.
Hepatogastroenterology. Mar-Apr 2001;48(38):382-386.
37. Gall Bladder Carcinoma
References
• Primrose JN, Fox R, Palmer DH et al. Adjuvant capecitabine for biliary tract
cancer: The BILCAP randomized study. Journal of Clinical Oncology 35, no.
15_suppl (May 20 2017) 4006-4006.
• Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy
useful for gallbladder carcinoma? A phase III multicenter prospective
randomized controlled trial in patients with resected pancreaticobiliary
carcinoma. Cancer. Oct 15 2002;95(8):1685-95.
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus
gemcitabine for biliary tract cancer. N Engl J Med. Apr 8 2010;362(14): 1273-
1281.
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts
response of solid tumors to PD-1 blockade. Science. Jul 28 2017;
357(6349):409-413.
entities that may also cause inflammation in the
gallbladder wall, such as APBJ, choledochal cysts, and PSC.
Extensive calcification of the wall of the gallbladder can cause a
brittle gallbladder wall, leading to what is termed porcelain gallbladder,
less than 10% of patients with porcelain gallbladder.
APBDJ-a long common channel, formed by an abnormally
proximal junction between the pancreatic and common bile ducts (CBDs),
and elevated sphincter of Oddi pressures create a predisposition to reflux
pancreatic exocrine secretions into the bile ducts.
APBDJ-a long common channel, formed by an abnormally
proximal junction between the pancreatic and common bile ducts (CBDs),
and elevated sphincter of Oddi pressures create a predisposition to reflux
pancreatic exocrine secretions into the bile ducts.
Papillary cancers tend to grow within the gallbladder lumen and are
less likely to invade the liver or to metastasize to lymph nodes; they are
associated with the best prognosis. Infiltrative or nodular cancers have a more
diffuse pattern of growth that is difficult to recognize on imaging studies.
These lesions are more likely to have invaded the liver and to have
metastasized to lymph nodes by the time of diagnosis.
venous drainage of the gallbladder includes direct venous tributaries
into the liver parenchyma, these tumors may spread directly
into segment IV of the liver. Transperitoneal spread is also
common and can progress to carcinomatosis
Symptoms of acute cholecystitis,
with obstruction of the neck of the gallbladder, may portend a
better prognosis because patients with these symptoms may
present with earlier stages of disease. Weight loss, jaundice, or an
abdominal mass is associated with later stages of disease. Some
patients describe symptoms of chronic cholecystitis in which the
pain has recently changed in quality or frequency. Other common
symptoms include chronic epigastric pain, early satiety, and a
sense of fullness.
Pain in right hypochondrium, mass in right upper abdomen
which is hard and nontender.
EUS, EUS guided tissue biopsy
In the setting of unresectability (portal
vein encasement or extensive hepatic involvement) or incurability
(hepatic or peritoneal metastases), percutaneous methods for confirmatory
tissue diagnosis should be used
PET is more sensitive than CT
for the detection of distant metastases, and therefore alters management in a
significant fraction of cases when used.12–14 PET is less useful in
differentiating benign versus malignant disease, and therefore is limited in its
ability to differentiate between residual disease and post-surgical changes
after cholecystectomy. While some favor the routine use of PET, others favor
using PET selectively to further evaluate indeterminate findings on CT or
MRI.
Lap is not performed due to risk of GB perforation and tumor spillage
T1a-carcinoma penetrates the
lamina propria but does not invade the muscle layer, cholecystectomy
should suffice for therapy.
The extended cholecystectomy is directed at obtaining an R0
resection of the disease, including the draining lymph node basins.
Therefore, removal of the pericholedochal, periportal, hepatoduodenal,
right celiac, and posterior pancreaticoduodenal lymph
nodes should be included. Resection of the cystic duct margin to
uninvolved mucosa may require resection of the common bile
duct with Roux-en-Y reconstruction. Because local extension into
the hepatic parenchyma is common, 2 cm of apparently normal
hepatic parenchyma from the gallbladder fossa is resected. As port
site recurrences have been reported for patients with even in situ
disease, all port sites should also be excised.
Ro- microscopically margin negative resection
R1-removal of macroscopic disease but microscopic margins are positive for tumor
R2-gross residual tumor that was not resected (primary tumor, regional nodes, and macroscopic margin involvement )
Frozen section biopsy from cystic duct
stump should be done to identify for the existence of microscopic
tumour. If present, CBD resection and hepaticojejunostomy hepaticojejunostomy
is done. Open approach rather than laparoscopic
is ideal for carcinoma gallbladder
T2
lesions, in which the cancer extends past the muscularis but not
beyond the serosa, a similar approach with radical cholecystectomy
is indicated because more than 40% of these patients have
lymph node metastases and up to 25% have positive margins
when treated with standard cholecystectomy alone. Because gallbladder
cancer is generally unresponsive to other therapies, the
presence of any residual disease after operative intervention predicts
poor outcome.2
tumors harboring defective mismatch repair were examined for response to
the anti–PD-1 antibody pembrolizumab
Common symptoms requiring palliation include jaundice,
pain, and intestinal obstruction
Jaundice-endoscopic biliary stenting, and self-expanding endobiliary metal
stents can provide a durable solution, with less need for repeated
interventions than with plastic stents.
BILCAP trial (university of Birmingham ) . includes- capecitabine 1250mg/m2 twicw daily on days 1-14 of a 21days cycle ,for 8 cycle ,or observation commencing within 16weeks of surgery ….but prevalence is 0.09 which is not significant .
Phase i- is treatment safe ?
Phase ii- whether treatment work?
Phase iii- whether treatment is safer than other option?
Phase iv- what else do we need to know
Phase iv-
5year survival is only 5%
Overall survival of gallbladder cancer < 15%.
Because most patients with gallbladder
cancer present with advanced disease, the overall survival
of gallbladder cancer is less than 15%.
5year survival is only 5%
Overall survival of gallbladder cancer < 15%.
Because most patients with gallbladder
cancer present with advanced disease, the overall survival
of gallbladder cancer is less than 15%.